×
About 20,740 results

ALLMedicine™ Neutropenia Center

Research & Reviews  6,081 results

Improved risk prediction of chemotherapy-induced neutropenia-model development and vali...
https://doi.org/10.1002/cam4.4465
Cancer Medicine; Venäläinen MS, Heervä E et. al.

Dec 4th, 2021 - The existing risk prediction models for chemotherapy-induced febrile neutropenia (FN) do not necessarily apply to real-life patients in different healthcare systems and the external validation of these models are often lacking. Our study evaluates...

Cost-effectiveness of home-based care of febrile neutropenia in children with cancer.
https://doi.org/10.1002/pbc.29469
Pediatric Blood & Cancer; Tew M, De Abreu Lourenco R et. al.

Dec 3rd, 2021 - Home-based treatment of febrile neutropenia (FN) in children with cancer with oral or intravenous antibiotics is safe and effective. There are limited data on the economic impact of this model of care. We evaluated the cost-effectiveness of implem...

Congenital neutropenia: disease models guiding new treatment strategies.
https://doi.org/10.1097/MOH.0000000000000696 10.1182/blood.2021010762.
Current Opinion in Hematology; Touw IP

Dec 3rd, 2021 - Myeloid diseases are often characterized by a disturbed regulation of myeloid cell proliferation, survival, and maturation. This may either result in a severe paucity of functional neutrophils (neutropenia), an excess production of mature cells (m...

Self-limiting severe neutropenia in a patient with COVID-19.
https://doi.org/10.1136/bcr-2021-247057
BMJ Case Reports; Singh R, Ratre BK et. al.

Dec 2nd, 2021 - Neutropenia is a rare haematological complication of COVID-19 infection in immunocompetent patients. There is sparse literature on neutropenia in patients with COVID-19, except a few case reports. We encountered a similar case in an intensive care...

see more →

Guidelines  15 results

Emerging challenges in the evaluation of fever in cancer patients at risk of febrile ne...
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7682766
Supportive Care in Cancer : Official Journal of the Multi... Cooksley T, Font C et. al.

Nov 25th, 2020 - Patients with cancer are at higher risk of more severe COVID-19 infection and have more associated complications. The position paper describes the management of cancer patients, especially those receiving anticancer treatment, during the COVID-19 ...

Management and Appropriate Use of Diazoxide in Infants and Children with Hyperinsulinism.
https://doi.org/10.1210/clinem/dgaa543
The Journal of Clinical Endocrinology and Metabolism; Brar PC, Heksch R et. al.

Aug 19th, 2020 - The diagnosis of hypoglycemia and the use of diazoxide have risen in the last decade. Diazoxide is the only Food and Drug Agency-approved pharmacologic treatment for neonatal hypoglycemia caused by hyperinsulinism (HI). Recent publications have hi...

ACR Appropriateness Criteria® Acute Nonlocalized Abdominal Pain.
https://doi.org/10.1016/j.jacr.2018.09.010
Journal of the American College of Radiology : JACR; , Scheirey CD et. al.

Nov 6th, 2018 - The range of pathology in adults that can produce abdominal pain is broad and necessitates an imaging approach to evaluate many different organ systems. Although localizing pain prompts directed imaging/management, clinical presentations may vary ...

Antimicrobial Prophylaxis for Adult Patients With Cancer-Related Immunosuppression: ASC...
https://doi.org/10.1200/JCO.18.00374
Journal of Clinical Oncology : Official Journal of the Am... Taplitz RA, Kennedy EB et. al.

Sep 5th, 2018 - To provide an updated joint ASCO/Infectious Diseases Society of America (IDSA) guideline on antimicrobial prophylaxis for adult patients with immunosuppression associated with cancer and its treatment. ASCO and IDSA convened an update Expert Panel...

Outpatient Management of Fever and Neutropenia in Adults Treated for Malignancy: Americ...
https://doi.org/10.1200/JCO.2017.77.6211
Journal of Clinical Oncology : Official Journal of the Am... Taplitz RA, Kennedy EB et. al.

Feb 21st, 2018 - Purpose To provide an updated joint ASCO/Infectious Diseases Society of American (IDSA) guideline on outpatient management of fever and neutropenia in patients with cancer. Methods ASCO and IDSA convened an Update Expert Panel and conducted a syst...

see more →

Drugs  243 results see all →

Clinicaltrials.gov  251 results

Ruxolitinib for Cancer Cachexia
https://clinicaltrials.gov/ct2/show/NCT04906746

Nov 30th, 2021 - Lung cancer patients on a whole, and a significant percentage of NSCLC patients in particular, develop cancer cachexia. In fact, approximately 30-40% of all NSCLC patients will develop cachexia in their disease course, with the highest percentages...

The Oral Cavity as a Source of Febrile Neutropenia
https://clinicaltrials.gov/ct2/show/NCT02702583

Nov 29th, 2021 - Febrile neutropenia (FN) is a clinically important adverse effect of myelosuppressive chemotherapy. If patients present with FN, attention is focussed on well-recognized sites of origin of infection: the airways, urinary tracts, and skin. However,...

Radium-223 Dichloride Long-term Follow-up Program
https://clinicaltrials.gov/ct2/show/NCT02312960

Nov 26th, 2021 - This long-term follow up study will enroll subjects who will be transferred from selected interventional, company sponsored trials with radium-223 dichloride (feeder trials). The primary objectives are to define the long term safety profile of rad...

Imipenem, Cilastatin Sodium, and Relebactam Monohydrate for the Treatment of Cancer Patients With Febrile Neutropenia
https://clinicaltrials.gov/ct2/show/NCT04983901

Nov 23rd, 2021 - PRIMARY OBJECTIVES: I. To evaluate the efficacy of imipenem, cilastatin sodium, and relebactam monohydrate (imipenem-relebactam) plus vancomycin, daptomycin or linezolid versus (vs) standard of care (SOC) plus vancomycin, daptomycin or linezolid a...

Clinical Trial of Brentuximab Vedotin in Classical Hodgkin Lymphoma
https://clinicaltrials.gov/ct2/show/NCT03646123

Nov 23rd, 2021 - This study will have three parts. Part A of the study is designed to evaluate the incidence of febrile neutropenia, efficacy, and dose intensity in participants with advanced stage classical Hodgkin lymphoma (cHL) receiving granulocyte colony stim...

see more →

News  1,705 results

Therapeutic Frontiers for Relapsed/Refractory Multiple Myeloma Expand With CAR T and Bispecific Antibodies
https://www.onclive.com/view/therapeutic-frontiers-for-relapsed-refractory-multiple-myeloma-expand-with-car-t-and-bispecific-antibodies

Dec 1st, 2021 - Multiple Myeloma is a clonal plasma cell neoplasm characterized by bone lesions, renal impairment, cytopenias, and immunodeficiency. Despite significant therapeutic advancements in the past 2 decades that have resulted in improved survival, myelom...

Efforts Needed to Evaluate How CAR T-Cell Therapy Recipients Respond to COVID-19 Vaccination
https://www.onclive.com/view/efforts-needed-to-evaluate-how-car-t-cell-therapy-recipients-respond-to-covid-19-vaccination

Dec 1st, 2021 - Although CAR T-cell therapy have resulted in unprecedented response rates in patients with hematologic malignancies, the modality comes with distinctive toxicities and infection risks that may impact the effectiveness of COVID-19 vaccines, accordi...

BO-112 Plus Pembrolizumab Improves ORR in Advanced Melanoma After Progression on Anti–PD-1 Therapy
https://www.onclive.com/view/bo-112-plus-pembrolizumab-improves-orr-in-advanced-melanoma-after-progression-on-anti-pd-1-therapy

Dec 1st, 2021 - The addition of BO-112 to pembrolizumab (Keytruda) produced clinical benefit in patients with unresectable malignant melanoma who have experienced disease progression on anti–PD-1 therapy, according to data from the preliminary analysis of the pha...

FDA Issues Complete Response Letter to Plinabulin for Chemo-Induced Neutropenia
https://www.onclive.com/view/fda-issues-complete-response-letter-to-plinabulin-for-chemo-induced-neutropenia

Dec 1st, 2021 - The FDA has issued a complete response letter (CRL) to the new drug application (NDA) seeking the approval of plinabulin in combination with granulocyte colony-stimulating factor (G-CSF) for the prevention of chemotherapy-induced neutropenia (CIN)...

Antimicrobial prophylaxis prevents life-threatening infections in children with AML receiving chemotherapy
https://www.mdedge.com/hematology-oncology/article/249260/aml/antimicrobial-prophylaxis-prevents-life-threatening

Dec 1st, 2021 - Key clinical point: Antimicrobial prophylaxis significantly reduced rates of bloodstream infection (BSI), invasive fungal infection (IFI), and febrile neutropenia (FN) in pediatric patients with acute myeloid leukemia (AML) receiving chemotherapy.

see more →

Patient Education  1 results see all →